GHRH analogue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-18. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
t1/2 is the elimination half life of the compound. tmax is the time to peak plasma levels after oral administration of amoxapine. CSS is the steady state plasma concentration. protein binding is the extent of plasma protein binding. Vd is the volume of distribution of the compound.
== International Cooperation == NCCD participates in global activities on matters of agri-logistics and food loss and waste. In 2013, Capt. Pawanexh Kohli, then head of NCCD, represented India as the Guest of Honour at the International Summit on Sustainability and cold chain in France, when NCCD also signed an MoU with Cemafroid. NCCD's first CEO was also invited for a debate at UK's House of Lords in 2015 and as expert to UK's Policy Commission on Cold Economy. That same year, NCCD's CEO co-chaired Working Groups on Food Loss and Food Waste at the International Action Summit held in The Hague. Under the authorship of its founding CEO, NCCD published India's minimum system standards and guidelines for cold chain infrastructure. NCCD also conducted the country's first ever cold chain infrastructure assessment, which thereafter formed the basis for future strategies in India. In 2016, NCCD was designated a knowledge partner of India's inter-ministerial Committee for Doubling Farmers' Income, with its CEO as a member of this historic Committee. NCCD has undertaken projects to demonstrate the efficiency of cold chain in connecting farmers with markets across India's sub-continental distances. Such projects also documented higher incomes for farmers and lower food losses and carbon footprint of the supply chain. Another initiative by NCCD is that of bringing synergistic uses to village level refrigerated pack-houses so as to benefit social and welfare needs of rural communities.
SSV run at partial atmospheres (typically around 1/3 of full atmospheric pressure) in a hybrid of vacuum and conventional kiln technology (SSV kilns are significantly more popular in Europe where the locally harvested wood is easier to dry versus species found in North America). RF/V (radio frequency + vacuum) kilns use microwave radiation to heat the kiln charge, and typically have the highest operating cost due to the heat of vaporization being provided by electricity rather than local fossil fuel or waste wood sources. Valid economic studies of different wood drying technologies are based on the total energy, capital, insurance/risk, environmental impacts, labor, maintenance, and product degrade costs for the task of removing water from the wood fiber. These costs (which can be a significant part of the entire plant costs) involve the differential impact of the presence of drying equipment in a specific plant. An example of this is that every piece of equipment (in a lumber manufacturing plant) from the green trimmer to the infeed system at the planer mill is the "drying system". Since thousands of different types of wood products manufacturing plants exist around the globe, and may be integrated (lumber, plywood, paper, etc.) or stand alone (lumber only), the true costs of the drying system can only be determined when comparing the total plant costs and risks with and without drying. The total (harmful) air emissions produced by wood kilns, including their heat source, can be significant.
In contrast, the border with Canada is primarily maintained through joint border patrol and security camera programs, making it the world's longest undefended border. In remote areas along the border with Canada, where staffed border crossings are unavailable, there are hidden sensors on roads, trails, railways, and wooded areas near crossing points. Members of the Schengen Agreement are required to apply strict checks on travellers entering and exiting the area. These checks are coordinated by the European Union's Frontex agency, and subject to common rules. The details of border controls, surveillance and the conditions under which permission to enter into the Schengen Area may be granted are exhaustively detailed in the Schengen Borders Code. All persons crossing external borders are subject to a check by a border guard. The only exception is for regular cross-border commuters (both those with the right of free movement and third-country nationals) who are well known to the border guards: once an initial check has shown that there is no alert on record relating to them in the Schengen Information System or national databases, they can only be subject to occasional 'random' checks, rather than systematic checks every time they cross the border. Additionally, border security in Europe is increasingly being outsourced to private companies, with the border security market growing at a rate of 7% per year.
Sources: en.wikipedia.org
Most polyphenols are metabolized by catechol-O-methyltransferase, and therefore do not have the chemical structure allowing antioxidant activity in vivo; they may exert biological activity as signaling molecules.
Seven people were killed in a Russian attack on the offices of Ukraine's largest printing house, located in Kharkiv. One person was killed in a separate attack in Zaporizhzhia Oblast. Russian-installed authorities in Crimea claimed that two people were killed in a Ukrainian missile attack in Simferopol Raion. The pro-Ukrainian partisan group Atesh claimed that the attack targeted a communications hub in Alushta, while other attacks were reported on a military antenna in Semydviria, Belbek airfield and in Yevpatoria. Ukraine claimed to have shot down a Russian Su-25 jet over the Donbas. Several sources questioned this claim, stating that the footage of the incident appeared to have been taken from a video game. Russia claimed to have shot down a drone over Tatarstan. Officials claimed that one person was killed in a drone strike in Belgorod Oblast. Norway pledged a $190 million military aid package to Ukraine that included support for air defense, naval capabilities, radar, anti-drone systems, and boats. Russia warned the UK that it could strike British targets "on Ukraine's territory and beyond its borders" if weapons it supplied to Ukraine are used against targets on Russian soil. The first group of Ukrainian pilots passed the US F-16 training program at Morris Air National Guard Base in Arizona and will undergo further training in Europe. Putin signed a decree allowing the assets of the United States, its citizens, and its companies to be confiscated and used for compensation for losses incurred by international sanctions.
Therefore, the Royal College of Pathologists and Royal College of Physicians have developed combined infection training, that medical trainees gain a much more patient focused experience, and undertake physician examinations in addition to pathology training. The result of this is that several regional medical deaneries no longer permit medical doctors to train in microbiology or virology as single disciplines, and instead advocate dual-specialisation as infectious disease/microbiology or infectious disease/virology. Simultaneously, the expansion of higher specialist scientist trainees in microbiology means that many of the laboratory and scientific responsibilities of medical doctors may be taken on by clinical scientists, and medical doctors will instead be expected to perform a much more patient facing role. The exception in microbiology is the sub-discipline of virology, which is well suited to the expertise of clinical scientists due to reliance on cutting-edge scientific methods, increasing use of specialised genetic technologies, and a technical understanding of virus biology, with a reduced emphasis on patient management compared with microbiology as a whole.
== History == Etifoxine was developed by Hoechst in the 1960s. It was introduced for medical use in France in 1979. Since at least 2000, etifoxine has been marketed by the French pharmaceutical company Biocodex. Following reports of post-marketing toxicity, the safety of etifoxine was reassessed by the French government and the European Medicines Agency (EMA). In January 2022, the EMA "finalized its review of Stresam and concluded that the medicine can continue to be used for the treatment of anxiety disorders, but it must not be used in patients who previously had severe skin reactions or severe liver problems after taking etifoxine."
==== Oral testosterone undecanoate ==== Instead of in its free unesterified form, testosterone is used by oral administration in the form of testosterone undecanoate. Due to the unique chemical properties afforded by its long fatty acid ester chain, this testosterone ester is partially absorbed from the gastrointestinal tract into the lymphatic system, thereby bypassing a portion of first-pass metabolism in the liver and producing measurable increases in testosterone levels at much lower doses than free testosterone. Of oral testosterone undecanoate that reaches circulation, 90 to 100% is transported lymphatically. However, its duration remains short, with an elimination half-life of 1.6 hours and a mean residence time of 3.7 hours. Oral testosterone undecanoate is provided as 40 mg oil-filled capsules and requires administration 2 to 4 times per day (i.e., 80 to 160 mg/day) for substitution in men. It must be taken with food containing at least a moderate or "normal" amount of fat in order to achieve adequate absorption. In addition, there is very high interindividual variability in levels of testosterone with oral testosterone undecanoate. The bioavailability of oral testosterone undecanoate taken with food is 3 to 7%. Inappropriately high levels of testosterone have been observed with 10 to 40 mg/day oral testosterone undecanoate in women. The oral bioavailability of testosterone undecanoate in young women after a single 40 mg dose was found to be 6.8 ± 3.3%.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.